Literature DB >> 32001135

Optimization of 8-oxoadenines with toll-like-receptor 7 and 8 activity.

Hélène G Bazin1, Laura S Bess2, Mark T Livesay2, Yufeng Li3, Van Cybulski4, Shannon M Miller5, David A Johnson3, Jay T Evans4.   

Abstract

Toll-like receptors 7 and 8 (TLR7/8) agonists are potent immunostimulants that are attracting considerable interest as vaccine adjuvants. We recently reported the synthesis of a new series of 2-O-butyl-8-oxoadenines substituted at the 9-position with various linkers and N-heterocycles, and showed that TLR7/8 selectivity, potency and cytokine induction could be modulated by varying the alkyl linker length and the N-heterocyclic ring. In the present study, we further optimized the oxoadenine scaffold by investigating the effect of different substituents at the 2-position of the oxoadenine on TLR7/8 potency/selectivity, cytokine induction and DC maturation in human PBMCs. The results show that introducing a 1-(S)-methylbutoxy group at the 2-position of the oxoadenine significantly increased potency for TLR7/8 activity, cytokine induction and DC maturation.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Oxoadenine; TLR7; TLR8; Toll-like-receptor

Mesh:

Substances:

Year:  2020        PMID: 32001135      PMCID: PMC7050994          DOI: 10.1016/j.bmcl.2020.126984

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  24 in total

1.  Therapy with TLR7 agonists induces lymphopenia: correlating pharmacology to mechanism in a mouse model.

Authors:  Hannah Perkins; Tansi Khodai; Houria Mechiche; Peter Colman; Frances Burden; Carl Laxton; Nigel Horscroft; Tom Corey; Deborah Rodrigues; Jaiessh Rawal; Jonathan Heyen; Mark Fidock; Mike Westby; Helen Bright
Journal:  J Clin Immunol       Date:  2012-04-05       Impact factor: 8.317

Review 2.  Imiquimod in dermatology: an overview.

Authors:  Edith Hanna; Rami Abadi; Ossama Abbas
Journal:  Int J Dermatol       Date:  2016-08       Impact factor: 2.736

Review 3.  Nucleolipids: natural occurrence, synthesis, molecular recognition, and supramolecular assemblies as potential precursors of life and bioorganic materials.

Authors:  Helmut Rosemeyer
Journal:  Chem Biodivers       Date:  2005-08       Impact factor: 2.408

4.  Synthesis and structure-activity-relationships of 1H-imidazo[4,5-c]quinolines that induce interferon production.

Authors:  John F Gerster; Kyle J Lindstrom; Richard L Miller; Mark A Tomai; Woubalem Birmachu; Shannon N Bomersine; Shiela J Gibson; Linda M Imbertson; Joel R Jacobson; Roy T Knafla; Peter V Maye; Nickolas Nikolaides; Folakemi Y Oneyemi; Gwen J Parkhurst; Sharon E Pecore; Michael J Reiter; Lisa S Scribner; Tracy L Testerman; Natalie J Thompson; Tammy L Wagner; Charles E Weeks; Jean-Denis Andre; Daniel Lagain; Yvon Bastard; Michel Lupu
Journal:  J Med Chem       Date:  2005-05-19       Impact factor: 7.446

5.  Discovery of 8-hydroxyadenines as a novel type of interferon inducer.

Authors:  Kosaku Hirota; Kazunori Kazaoka; Itaru Niimoto; Hiroshi Kumihara; Hironao Sajiki; Yoshiaki Isobe; Haruo Takaku; Masanori Tobe; Haruhisa Ogita; Tetsuhiro Ogino; Shinji Ichii; Ayumu Kurimoto; Hajime Kawakami
Journal:  J Med Chem       Date:  2002-12-05       Impact factor: 7.446

6.  Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7.

Authors:  Jongdae Lee; Tsung-Hsien Chuang; Vanessa Redecke; Liping She; Paula M Pitha; Dennis A Carson; Eyal Raz; Howard B Cottam
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-08       Impact factor: 11.205

7.  Structure-activity relationships of adenine and deazaadenine derivatives as ligands for adenine receptors, a new purinergic receptor family.

Authors:  Thomas Borrmann; Aliaa Abdelrahman; Rosaria Volpini; Catia Lambertucci; Edgars Alksnis; Simone Gorzalka; Melanie Knospe; Anke C Schiedel; Gloria Cristalli; Christa E Müller
Journal:  J Med Chem       Date:  2009-10-08       Impact factor: 7.446

8.  Synthesis and evaluation of 2-substituted 8-hydroxyadenines as potent interferon inducers with improved oral bioavailabilities.

Authors:  Ayumu Kurimoto; Tetsuhiro Ogino; Shinji Ichii; Yoshiaki Isobe; Masanori Tobe; Haruhisa Ogita; Haruo Takaku; Hironao Sajiki; Kosaku Hirota; Hajime Kawakami
Journal:  Bioorg Med Chem       Date:  2004-03-01       Impact factor: 3.641

Review 9.  Recent advances of vaccine adjuvants for infectious diseases.

Authors:  Sujin Lee; Minh Trang Nguyen
Journal:  Immune Netw       Date:  2015-04-23       Impact factor: 6.303

10.  Synthetic Toll-like Receptors 7 and 8 Agonists: Structure-Activity Relationship in the Oxoadenine Series.

Authors:  Jay T Evans; Laura S Bess; Sandra C Mwakwari; Mark T Livesay; Yufeng Li; Van Cybulski; David A Johnson; Hélène G Bazin
Journal:  ACS Omega       Date:  2019-09-10
View more
  3 in total

1.  Development of a TLR7/8 agonist adjuvant formulation to overcome early life hyporesponsiveness to DTaP vaccination.

Authors:  David J Dowling; Soumik Barman; Alyson J Smith; Francesco Borriello; Danielle Chaney; Spencer E Brightman; Gandolina Melhem; Byron Brook; Manisha Menon; Dheeraj Soni; Simone Schüller; Karthik Siram; Etsuro Nanishi; Hélène G Bazin; David J Burkhart; Ofer Levy; Jay T Evans
Journal:  Sci Rep       Date:  2022-10-18       Impact factor: 4.996

2.  Discovery of new TLR7 agonists by a combination of statistical learning-based QSAR, virtual screening, and molecular dynamics.

Authors:  Ardavan Abiri; Masoud Rezaei; Mohammad Hossein Zeighami; Younes Vaezpour; Leili Dehghan; Maedeh KhorramGhahfarokhi
Journal:  Inform Med Unlocked       Date:  2021-11-15

3.  Using Dual Toll-like Receptor Agonism to Drive Th1-Biased Response in a Squalene- and α-Tocopherol-Containing Emulsion for a More Effective SARS-CoV-2 Vaccine.

Authors:  Kristopher K Short; Stephanie K Lathrop; Clara J Davison; Haley A Partlow; Johnathan A Kaiser; Rebekah D Tee; Elizabeth B Lorentz; Jay T Evans; David J Burkhart
Journal:  Pharmaceutics       Date:  2022-07-12       Impact factor: 6.525

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.